GENE ONLINE|News &
Opinion
Blog

2026-05-06|

Knight-Swift Announces $1.3 Billion Convertible Senior Notes Offering Maturing in 2029

by GOAI
Share To

Knight-Swift Transportation Holdings Inc. recently announced the pricing of an upsized offering of convertible senior notes, totaling $1.3 billion. The notes will mature on May 15, 2029, and bear an annual interest rate of 1.75%.

The sale is expected to close on May 8, 2026, subject to customary closing conditions. Knight-Swift also granted the initial purchasers of the notes an option to purchase up to an additional $200 million aggregate principal amount of the notes. The notes are being offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The interest will be payable semi annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2026. Prior to February 15, 2029, the notes will be convertible only upon the occurrence of certain events and during certain periods, and will be convertible thereafter at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Knight-Swift intends to use the net proceeds from the offering to redeem its outstanding 6.00% Senior Notes due 2027 and for general corporate purposes, which may include acquisitions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 6, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
Ellomay Capital Completes Sale of Dorad Energy Holdings on May 10, 2026
2026-05-10
Digitalis Glycosides Studied for Heart Failure Treatment at ESC Heart Failure 2026 Congress
2026-05-10
Digoxin Lowers Death Risk and Heart Failure in Rheumatic Heart Disease Patients, Study Finds
2026-05-10
New Test Detects Biomarkers for Frontotemporal Lobar Degeneration, a Rare Dementia Affecting Over 57 Million Globally
2026-05-10
India’s Pharmaceutical Growth Slows: Industry Needs New Strategies
2026-05-10
MoonLake Immunotherapeutics Concludes Pre-BLA Meeting with FDA and Reports Q1 2026 Financial Results
2026-05-10
New Method Allows Repeated Genetic Data Extraction From Living Cells Without Destruction
2026-05-10
Scroll to Top